PRKAR1B and neoplasm: To test the efficiency of liposomal nanoparticles in delivering siRNA to the tumor target site, we performed quantitative reverse transcription PCR to determine PRKAR1B-AS expression level following administration of DOPC-control siRNA or DOPC-PRKAR1B-AS2-siRNA.